"We are proud to commercially launch Cipremi today (on Wednesday); amongst the lowest priced globally, and aim to supply over 80,000 vials ...

Gilead has issued licences to nine generic drug companies to make and sell remdesivir. Six of the companies are Indian - Hetero, Cipla, Dr ...

Written informed consent of each patient is required before the use of the drug while active post-marketing surveillance data and reporting...

The company is set to deliver the first set of 20,000 vials in two equal lots of 10,000 each, one of which will be immediately supplied to ...

The recommended course for a Covid-19 patient under oxygen support is five vials. The approved therapy is for moderate to severe patients.

Cipla, Hetero, and Jubilant Lifesciences have signed voluntary licensing agreements with Gilead.

NPPA has sent show-cause notices to these companies alleging overcharging for the combination drug used to treat the potentially fatal Hepa...

"Cipla FY16 guidance of 20-22 per cent revenue growth and 100 to 150 bps margin improvement for this year does not include InvaGen"

Cipla said the group, through its subsidiary Camber Pharmaceuticals Inc., will continue to strengthen its operations in the US.

People close to the transaction said Cipla will buy Invagen and Camber, Hetero’s wholly owned subsidiary, for about $550 million.

"Cipla's portfolio is of a commodity generics type; so this will definitely place it in a strong position in terms of product pipeline in t...

Hyderabad based Hetero pharma has launched biosimilar drug Rituximab under the brand name of MABALL, used in the treatment of blood cancer.

Hyderabad-based drug company Natco Pharma, which launched its anti-HINI drug 'Natflu' in the national capital, said it is talking with vari...

Natco is in race to bag a government contract for supply of 10 million Tamiflu, used to treat swine flu.

Hetero Drugs has pipped Ranbaxy Laboratories, Cipla, Natco Pharma, Strides Arcolabs and Roche India to bag half the government order to sup...

Blockbuster AIDS drug Tenofovir is set to get cheaper after its inventor and US patent holder Gilead struck non-exclusive licensing deals w...